Ad is loading...
AURX
Price
$0.78
Change
+$0.05 (+6.85%)
Updated
Nov 15 closing price
KRBP
Price
$1.00
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

AURX vs KRBP

Header iconAURX vs KRBP Comparison
Open Charts AURX vs KRBPBanner chart's image
Nuo Therapeutics
Price$0.78
Change+$0.05 (+6.85%)
Volume$118
CapitalizationN/A
Kiromic BioPharma
Price$1.00
Change-$0.00 (-0.00%)
Volume$5.18K
CapitalizationN/A
AURX vs KRBP Comparison Chart
Loading...
View a ticker or compare two or three
VS
AURX vs. KRBP commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURX is a Hold and KRBP is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (AURX: $0.78 vs. KRBP: $1.00)
Brand notoriety: AURX and KRBP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURX: 3% vs. KRBP: 314%
Market capitalization -- AURX: $36.23M vs. KRBP: $1.55M
AURX [@Biotechnology] is valued at $36.23M. KRBP’s [@Biotechnology] market capitalization is $1.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURX’s FA Score shows that 0 FA rating(s) are green whileKRBP’s FA Score has 0 green FA rating(s).

  • AURX’s FA Score: 0 green, 5 red.
  • KRBP’s FA Score: 0 green, 5 red.
According to our system of comparison, both AURX and KRBP are a bad buy in the long-term.

Price Growth

AURX (@Biotechnology) experienced а -2.81% price change this week, while KRBP (@Biotechnology) price change was +3.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

KRBP is expected to report earnings on May 12, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
AURX($36.2M) has a higher market cap than KRBP($1.55M). AURX YTD gains are higher at: 41.364 vs. KRBP (14.943). AURX has higher annual earnings (EBITDA): -2.59M vs. KRBP (-16.53M). KRBP has more cash in the bank: 4.05M vs. AURX (473K). AURX has less debt than KRBP: AURX (194K) vs KRBP (13.4M). AURX has higher revenues than KRBP: AURX (1.03M) vs KRBP (0).
AURXKRBPAURX / KRBP
Capitalization36.2M1.55M2,342%
EBITDA-2.59M-16.53M16%
Gain YTD41.36414.943277%
P/E RatioN/AN/A-
Revenue1.03M0-
Total Cash473K4.05M12%
Total Debt194K13.4M1%
FUNDAMENTALS RATINGS
AURX: Fundamental Ratings
AURX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
PROFIT vs RISK RATING
1..100
80
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JACRX13.73N/A
N/A
Easterly Global Real Estate C
DGFCX28.19-0.13
-0.46%
Davis Global C
AIIYX23.00-0.28
-1.20%
Invesco EQV International Equity Y
SNXFX127.13-1.68
-1.30%
Schwab 1000 Index®
RUSRX11.57-0.17
-1.45%
Lazard US Systematic Small Cap Eq R6

AURX and

Correlation & Price change

A.I.dvisor tells us that AURX and ALZN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AURX and ALZN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURX
1D Price
Change %
AURX100%
+7.06%
ALZN - AURX
30%
Poorly correlated
-6.85%
VRAX - AURX
27%
Poorly correlated
-5.79%
NCNA - AURX
26%
Poorly correlated
-3.87%
FENC - AURX
23%
Poorly correlated
-9.32%
KRBP - AURX
22%
Poorly correlated
N/A
More

KRBP and

Correlation & Price change

A.I.dvisor tells us that KRBP and MCRB have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KRBP and MCRB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRBP
1D Price
Change %
KRBP100%
N/A
MCRB - KRBP
27%
Poorly correlated
-7.16%
ENLV - KRBP
25%
Poorly correlated
-0.93%
VKTX - KRBP
25%
Poorly correlated
-7.45%
ALLO - KRBP
24%
Poorly correlated
-7.72%
XRTX - KRBP
24%
Poorly correlated
-8.02%
More